The in vitro responses of T cells from 13 
Introduction
Patients with insulin-dependent type I diabetes are treated with either heterologous beef insulin (BI)' and pork insulin (PI), or homologous (semisynthetic or recombinant) human insulin (HI). Anti-insulin antibodies are detectable in most of these patients (1, 2) . Insulin-specific antibodies have been detected in some patients even before the onset ofthe disease and insulin treatment (3, 4) . This shows that BI, PI, and HI are immunogenic in humans. In fact, in 1 out of 10,000 type I diabetics, high-titered anti-insulin serum antibodies ofthe IgG subclass may even elicit immunologic insulin resistance (IIR) 1 . Abbreviations used in this paper: APC, antigen-presenting cell; BI, beef insulin; GAT, random terpolymer of glutamic acid60, alanine30, tyrosine"'; HI, human insulin; IAA, insulin autoantibody; IIR, immunologic insulin resistance; OVA, ovalbumin; PI, pork insulin; PPD, purified protein derivative; SBI, sulfated beef insulin; TT, tetanus toxoid.
(1). Treatment of diabetics with a hormonally active yet nonimmunogenic form of insulin is therefore highly desirable. We show here that treatment of an IIR type I diabetic patient with sulfated beef insulin (SBI) caused the level of insulin required to maintain this patient to decrease dramatically within 1 yr. This occurred in parallel to a marked decrease (undetectable) in both her serum levels of anti-insulin antibodies and her in vitro T cell proliferative response to insulin, and the emergence of her insulin-reactive CD8' regulatory T cells. CD8' T cells that regulate responsiveness to insulin were also detected in 2 of 13 additional insulin-nonresistant type I diabetic patients tested. These two patients did not receive SBI treatment, possessed high titers of anti-insulin serum IgG antibodies, and their CD8' T cells were not insulin specific. These data provide further insight into the design of a bioactive, nonimmunogenic form of HI for the treatment of type I diabetes.
Methods
Patients. 1 immunologically insulin-resistant patient (L.B.) and 13 other insulin-nonresistant type I diabetic patients treated either at the Women's College Hospital Endocrinology Clinic or at H6pital Michel Levy Endocrinology Clinic were studied. The clinical data of these patients are summarized in Table I . Studies were approved by the institutional Human Subjects Research Review Committee, and written informed consent was obtained from each patient before blood sampling. Dr. A. Kenshole (Women's College Hospital, Toronto, Ontario, Canada) and Dr. B. Vialettes (Hopital Michel Levy, Marseille, France) were the consultant physicians for these patients.
Antigens. Monocomponent, zinc-free, crystalline PI, BI, and HI, as well as SBI, were obtained from Connaught Novo Ltd. (Willowdale, Ontario, Canada). Recombinant human insulin was generously provided by Eli Lilly Canada Inc. (Scarborough, Ontario, Canada). Insulin was reconstituted in 0.06 M HCI, pH 5, aliquotted, and lyophilized. Tetanus toxin (TT; 5,000 Lf/ml) was obtained from CalbiochemBehring Hoechst (La Jolla, CA). Both ovalbumin (OVA) and the random terpolymer of glutamic acid', alanine30, tyrosine'" (GAT) were purchased from Sigma Chemical Co. (St. Louis, MO).
Antibodies. Purified mouse anti-human CD8 and mouse antihuman CD4 MAbs were obtained from Ortho Pharmaceuticals Canada (Willowdale, Ontario, Canada). Culture supernatant from the MCT 4 anti-human CD8-producing mouse B hybridoma was kindly provided by Dr. Tak Mak, Ontario Cancer Institute (Toronto, Ontario, Canada), and was also used in T cell proliferation assays. In the latter assays dose titration curves of the anti-CD4 and anti-CD8 antibodies (starting concentration, 10 gg/ml) were generated to determine their effect on insulin-specific in vitro T cell proliferative responses. Mouse ascites fluid containing anti-CD4 (13.B8.2) or anti-CD8 (10.D1 1.5) MAbs (5) were kindly provided by Dr. D. Olive (U1 19, Institut Nationale de la Sante et de la Recherche Medicale, Marseille, France) and used for the cell depletion experiments described below. The 82C mouse anti-I-Ak MAb (6) was found to react with HLA class II molecules expressed by an EBV-transformed lymphoblastoid B cell line established from patient L.B.
Anti-insulin antibody response. The anti-insulin serum IgG antibody response of most of the patients studied, reported as units/milli- Cell depletion. Cells were incubated (107/ml) with a 1:100 dilution of ascites containing either an anti-CD4 (13.B8.2) or anti-CD8 (I0.DI 1.5) MAb for 30 min at 4VC and then washed. Cells were mixed with goat anti-mouse Ig-coated magnetic beads (0.1 ml beads/107 cells; Dynal, Inc., Great Neck, NY) for 30 min, and bead-adherent cells were subsequently removed with a magnet. Cell recovery was higher than in panning experiments. Purity of CD4' and CD8' subsets was established by flow cytometry on an ODAM ATC 3000 flow cytometer using an FITC-coupled rabbit anti-mouse IgG (Silenus, Eurobio, France) as a second step reagent. Generally, depleted cells were found to be > 95% enriched for the CD4-or CD8-phenotypes, respectively, and were used as such in experiments.
Results
Immunologic insulin-resistant type I diabetic patient. Patient L.B. was an HLA-DR 3/4 (Dw1 3, DQw2/w3) 21-yr-old female who developed type I diabetes at the age of 2. Her parents and brother (age 17; HLA identical to L.B.) are currently nondiabetic. However, her mother and her mother's identical twin sister both had hypo-and hyperthyroid dysfunction. At the end of 1982, after several years of insulin treatment, L.B. presented with acute insulin resistance. She was minimally over ideal body weight and showed a marked increase in insulin requirements without evidence of accompanying acanthosis nigricans or any endocrinopathy or infection. From 1983 to 1987 we monitored her immunological and endocrinological status and grouped these analyses into four different time periods ( Fig. 1) according to her levels of anti-insulin antibody production and type of insulin treatment. During the first period (January 1983-June 1984), her severe resistance to insulin was ascribed to a high titer (15,000 gU/ml) of anti-insulin antibodies ( Fig. 1 A) . At the time, her maintenance dose of 130 U/d of Lente regular insulin (BI plus PI) was excessively high (Fig. 1 C) , and her level of glycosylated hemoglobin (19.6%) was markedly elevated (Fig. 1 D) . L.B. was treated with steroid (10 mg prednisone/d) for 10 d, after which her antibody titer decreased to 7,200 MU/ml. She was subsequently maintained on 85 U/d of Lente insulin until May 1983 when her antibody titer rose to 16,300 ,U/ml. She was then treated successively during 1 1/2 yr with purified PI (77 and 105 MU/d) and Humulin (recombinant HI; 95 U/d) with no evidence of reduction of her anti-insulin antibody titer. In fact, her antibody titer reached a peak of 47,000 ,U/ml in June 1984 while she was still being treated with Humulin ( Fig. 1 A) used at 500 yg/ml. Results were quantitated by [3H]TdR incorporation, and SD were < 12% of the geometric mean. The positive control responses to the GAT (used at 1 mg/ml) and TT (used at 1 U/ml) antigens ranged from 7,000 to 21,000 cpm throughout this study, with the exception that after steroid therapy at the beginning of period 2 these antigens elicited responses of -3,000 cpm. No antigen control responses ranged from 500-1,500 cpm, with the exception that responses of about 4,000-6,000 cpm were noted for most (January 1986-November 1986) of period 3. The times at which the in vitro analyses of interaction between CD4' and CD8' T cells were performed are presented (arrows). C, The type and maintenance dose of insulin and duration of treatment are shown. Prednisone was administered at a dose of 10 mg/d for 10 d during the months indicated (n). D, Levels of glycoslyated hemoglobin (HbA1c) were determined by a Corning electrophoretic procedure (28) (normal range, 5.6-7.4%). (Fig. 1 B) (Table II) . No significant effect of anti-CD8 treatment on her responses to OVA, GAT, and TT was noted. In contrast, her responses to these antigens were reduced by the addition of anti-CD4. This reduction was significant only for the OVA and GAT responses, but in two other experiments (not shown) her T cell response to TT was also significantly decreased (0.2-fold response). The anti-CD8-induced enhanced response of L.B.'s T cells is specific since this treatment did not increase the responses ofT cells from 13 other type I diabetic patients. Table II demonstrates that the responses of three of these patients to the various antigens tested were reduced significantly in the presence of anti-CD4 but not anti-CD8. These data suggest that CD4+ and CD8+ T cell subpopulations proliferate simultaneously in culture, with a predominant growth ofCD4+ T cells. However, in the case of LB a functionally dominant CD8+ T cell subpopulation prevented the activation of a CD4+ T cell subset.
This result raised the possibility that the activity of L.B.'s CD8+ T cells might have increased to a detectable level after April 1986. Indeed, between January and March 1986 (beginning of period 3; see Fig. 1 ) we noted a transient in vitro primary T cell response to insulin (HI, PI, and BI) that could be inhibited by either anti-CD4 or anti-I-Ak (Table III, TT was used as a positive control antigen both anti-CD4 and anti-CD8 inhibited T cell proliferation. In contrast, both anti-CD4 and anti-CD8 inhibited L.B.'s in vitro secondary T cell responses to insulin (PI , Table III, experiment 2) . Similarly, these MAbs completely inhibited the secondary T cell responses to TT. Although the direct action of purified CD8+ T cells was not tested in culture at this time, both the greater inhibition of a primary response noted with anti-CD4 rather than anti-CD8 and the inability of anti-CD8 to enhance T cell responsiveness to insulin suggest that CD8+ regulatory T cell activity was insignificant at the beginning of period 3. This relative lack of CD8+ T cell activity also coincides with the transient increase in anti-insulin antibody activity noted during this time (Fig. 1 A) .
To further investigate the function of L.B.'s CD8+ T cells, we assayed the activity of her CD4+ and CD8+ T cells enriched (-85-90% pure) by panning. The responses of her CD4+ T cells to HI and SBI were enhanced about twofold by anti-CD8 treatment (Fig. 2) , whereas this treatment enhanced the CD4+ T cell responses to OVA, GAT, and TT only marginally (1.2-fold). These results demonstrate the presence of residual CD8+ T cells in the CD4+ T cell subpopulation and also identify a regulatory role for CD8+ T cells in a CD4+ T cell-mediated, insulin-specific response.
We next analyzed the insulin-specific proliferative responses of L.B.'s T cells obtained by the addition of increasing numbers of CD8+ T cells to a constant number (105) of CD4+ T cells (Fig. 2) . Maximal suppression of the responses to HI and SBI was obtained upon the addition of 105 CD8+ T cells (i.e., at a ratio of one CD8+ T cell to one CD4+ T cell). The addition of anti-CD8 to the latter T cell cultures reconstituted the insulin-specific proliferation to a level somewhat higher than that seen with anti-CD8-treated CD4+ T cells. These data indicate that CD4+ and CD8+ T cells interact to regulate the net immune response to insulin in this patient. L.B.'s CD4+ T cell responses to OVA (Fig. 2) For these patients CD41 and CD8' T cell depletion was optimized using magnetic beads (see Methods) and checked by flow cytometry (> 95% pure CD4' and CD8' T cell populations were obtained). Our results demonstrate that both A.K. and I.B. displayed T cell reactivity to various forms of insulin, the highest response being obtained to BI (Fig. 3 A) . This result was obtained in two (patient I.B.) or three (patient A.K.) separate experiments using either total T cells (Fig. 3, A and D) or purified CD4' T cells (Fig. 3, B, C , and E). The level of reactivity to HI (100 jg/ml) was between two and five times the background level of proliferation.
When increasing numbers of CD8+ T cells were added to the CD4+ T cell/APC cell culture, we observed a progressive decrease in the CD4+ T cell response to BI (Fig. 3, B and E). CD8+ T cells did not proliferate in the presence of APC and antigen (data not shown). A maximum suppressive effect was observed when a ratio of 0.2 to 1 CD8+ T cell per CD4+ T cell was used. The CD8+ T cell-mediated suppression noted for patients A.K. and I.B. was not specific for BI since an inhibitory effect was also observed when GAT but not purified protein derivative (PPD) (Fig. 3 C) was used as antigens. This CD8+ T cell-mediated suppression to BI, GAT, and PPD was eliminated by the addition of anti-CD8 to cultures containing CD4+ T cells, CD8+ T cells, and APC (Fig. 3, C and F) . This result is similar to that obtained for patient L.B. (Fig. 2) , with the exception that L.B.'s CD8* T cell-mediated suppressive effect was apparently specific for insulin. Note that the CD8+ T cell-mediated suppression of patient G.S. CD4+ T cell responses to GAT and PPD was less (Fig. 3 F) than that observed for patient A.K. (Fig. 3 C) . Patient G.S., a healthy, nondiabetic individual, did not mount a significant in vitro CD4+ T cell response to BI.
Immunogenicity ofSBI. Previously we reported that L.B. The data shown in experiments 1 and 2 were reproducible in repeat expenments. 
Discussion
These results demonstrate that sulfation of BI reduces its immunogenicity for insulin A-loop-specific T cells in mouse and man. SBI was ineffective at stimulating the in vitro proliferation of T cells from 13 insulin-nonresistant type I diabetic patients. Our data also show that IIR in a type I diabetic patient may be abrogated by regulatory CD8+ T cells elicited by her treatment with SBI. The emergence of these CD8+ T cells coincided with an impairment of her CD4+ T cell responsiveness to insulin and anti-insulin antibody production, both of which contributed to the elimination of her resistance to insulin therapy. It is interesting to extend these observations to an examination of other such insulin resistant diabetics, but such patients are rare. L.B. is the only type I diabetic in Canada whom we know is immunologically insulin resistant and who has been available to us for long-term immunological monitoring. Some immunologically insulin-resistant diabetics undergo spontaneous remission of this resistance without requiring SBI treatment (13) . However, this was not the case for patient L.B.
The pattern of nonresponsiveness to insulin noted for patient L.B. is similar to that observed in H-2b mice, which are genetic low responders to PI but possess both PI-specific helper T cells and dominant suppressor T cells that crossreact with mouse insulin ( 14, 15) . It was proposed that these suppressor T cells recognize A-chain-loop-associated epitopes of pork and mouse insulin, and that their dominant effect results in the PI low responder phenotype of these mice (14, 16) . Thus, in both humans and mice it is apparent that immunization with a nonimmunogenic form of insulin in a permissive MHC haplotype may activate dominant regulatory T cells that recognize autologous insulin. Suppressor T cells may inhibit the ability of helper T cells to stimulate B cells to produce antibodies ( 14) , and suppressor T cell lines may block in vitro proliferation of antigen-specific helper T cells (17) . L.B.'s CD8+ T cells therefore seem to function as suppressor T cells, since the decrease in her anti-insulin antibody production paralleled the appearance of her CD8+ T cells.
It was difficult to demonstrate insulin-specific suppressor activity of CD8' T cells obtained from 11 other insulinnonresistant type I diabetics. Such patients may possess peripheral CD8+ T cells that regulate their immune response to insulin, but the low frequency of such cells may preclude detection of their activity in vitro. In fact, the activity of such insulin-reactive regulatory CD8+ T cells may vary with the age of a patient. It is of interest in this regard that the level of insulin autoantibody (IAA) production is a predictive marker for type I diabetes, but usually only before puberty (18 We did, however, detect the presence ofCD8' regulatory T cells in two type I diabetic individuals, A.K. and I.B., who were maintained by treatment with HI, possessed high titers of anti-insulin serum antibodies, did not develop IIR, and displayed only a weak in vitro T cell response to insulin. The specificity of CD8' T cells from these patients was less restricted to insulin since these cells suppressed the response of CD4' T cells to both insulin and GAT, and to PPD to a lesser extent. Several mechanisms may account for this apparent lack of CD8' T cell antigen specificity. First, as has been observed in leprosy patients, both monocytes (antigen nonspecific) and CD8' T cells (antigen specific) can suppress immune responsiveness ( 19) . Note that monocytes/macrophages were present in our cultures of selected CD4' and CD8' T cell subpopulations. Second, CD8' T cells may function as cytotoxic cells directed against either CD4' T cells (20) We excluded the possibility that CD8' T cells simply absorbed all the IL-2 in culture required for the proliferation of CD4' T cells, since CD4' T cells grew well in cultures that contained CD8' T cells and to which graded numbers of IL-2-dependent CTLL cells were added. Third, the MHC haplotype of an individual may influence the responsiveness of her/his CD8+ T cells. The differences in the specificities of the CD8+ T cells observed between these patients could therefore be due to their expression of distinct MHC class II restricting elements (i.e., DR2 vs. DR 3/4). Fourth, our data are also similar to those reported recently for a CD8+ T cell-mediated suppression of the expression of the Igh-Ib allotype in mice. In this study the in vivo injection of an anti-CD8 antibody depleted the subset of CD4-8+ peripheral T cells, increased the relative activity of helper T cells, and enhanced Igh-lb positive Ig production (22) . In summary, these results are consistent with the idea that the net balance of activities of CD4+ and CD8+ T cells regulates the level of immune responsiveness to insulin in these patients.
Sulfation of insulin adds sulfate groups (average of six out of a possible eight per molecule) to side chains of threonine, serine, and tyrosine residues (23, 24) . Certain of these modifications are situated in regions of the A-and B-chain that we have shown contribute to the formation of three immunodominant conformational epitopes of insulin recognized by human T cells (9) . SBI is much less immunogenic both in vivo (23) (24) (25) and in vitro (this report) than either BI or PI. Addition of many negatively charged groups to insulin may alter its tertiary conformation, kinetics, and pathway of processing by an APC, or the capacity of a processed fragment(s) either to bind to HLA-D region encoded class II antigens or to be recognized with sufficient avidity by helper T cell antigen receptors.
Based on our results obtained with the responses of A-chainloop-reactive human and mouse T cells to SBI and BI (Table  IV) , we favor the possibility that a change in the conformation of the A-loop epitope of SBI is largely responsible for its reduced immunogenicity. This proposed change in conformation is also supported by the demonstration that the insertion of negatively charged residues into human insulin, by site-specific mutagenesis at some of the same residues (e.g., B9, B26, B27) that may be modified in SBI, converts insulin from a multimeric to a monomeric form that is absorbed two to three times faster after subcutaneous injection in vivo (26) .
SBI is currently manufactured by treatment of BI with H2SO4 for 20 min at room temperature (23, 27 ). When SBI is chromatographed by HPLC on a reverse-phase C18 column using various buffer systems, several poorly resolved peaks are observed (Naquet, P., unpublished observations). It has not been possible to identify which of these peaks is the active moiety or to establish whether all or only some of the BI residues listed above need to be sulfated to abolish the immunogenicity of BI in humans. Since we and others have shown that recombinant HI can on occasion provoke T cell and IgG antibody activity to insulin in type I diabetics, it would be advantageous to introduce structural modifications in this product to render it less immunogenic. In conclusion, the data presented here point the way for future attempts to modify HI either chemically or by site-specific mutagenesis (26) to derive a hormonally active and nonimmunogenic form of insulin to improve the maintenance of type I diabetic patients.
